Pfizer Inc.

113 articles about Pfizer Inc.

• Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference

  1/5/2021

  Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer leadership at the 39 th Annual J.P. Morgan Healthcare Conference to be held virtually. Albert Bourla, Chairman and Chief Executive Officer, will participate in a fireside chat presentation on Tuesday, January 12, 2021 at 10:00 a.m. EST. Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, wi

• LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA

  12/28/2020

  LORBRENA ® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA Supplemental New Drug Application being reviewed under FDA Real-Time Oncology Review (RTOR) and Project ORBIS pilot programs Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA

• Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health

  12/28/2020

  Myovant and Pfizer to jointly develop and commercialize ORGOVYX™  (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time

• Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine

  12/21/2020

  COMIRNATY ® (also known as BNT162b2) receives conditional marketing authorization from the European Commission; this milestone represents a global joint effort to advance the first authorized mRNA vaccine

• Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.

  12/10/2020

  FDA expected to make a decision on Emergency Use Authorization in the coming days Positive vote based on totality of scientific evidence presented by the companies, including Phase 3 efficacy and safety data If authorized, BNT162b2 would be the first COVID-19 vaccine available in the U.S.

• Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China

  11/19/2020

  Pfizer, Inc. (NYSE: PFE) and LianBio announced today that they have entered into a collaboration aimed at developing and commercializing transformative pharmaceutical products in Greater China. LianBio, founded by Perceptive Advisors, forged a collaboration with Pfizer to pursue an innovative business development opportunity. Both companies will be dedicated to advancing best-in-class therap

• Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan

  11/16/2020

  Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitu

• Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg

  11/12/2020

  Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL ® 80 mg/VYNDAMAX ® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg

• Pfizer Vaccine Coming Soon but Pandemic Not Over, States Physicians for Civil Defense

  11/10/2020

   Pfizer has announced that early results in its COVID-19 vaccine trial show an astonishing 90 percent efficacy , notes Physicians for Civil Defense. "In 10 years only three other vaccines with efficacy greater than 50 percent  have been developed." Of about 40,000 volunteers who received two doses of the experimental vaccine, 9

• U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis

  9/28/2020

  Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were app

• Pfizer Declares Fourth-Quarter 2020 Dividend

  9/24/2020

  The board of directors of Pfizer Inc. (NYSE:PFE) declared a 38-cent fourth-quarter 2020 dividend on the company’s common stock, payable December 1, 2020, to holders of the Common Stock of record at the close of business on November 6, 2020. The fourth-quarter 2020 cash dividend will be the 328 th consecutive quarterly dividend paid by Pfizer.

• Javelin Biotech Aims to Develop Industry-Leading “Organ-on-a-Chip” Predictive Pharmacokinetics Platform in Collaboration with Pfizer Inc.

  9/23/2020

  Javelin Biotech (“Javelin”) today announces a three-year collaboration with Pfizer Inc. (NYSE: PFE) to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules. The ADME platform will integrate

• FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma

  9/23/2020

  Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI® (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic

• OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib

  9/21/2020

  OnKure, Inc. , a leader in discovery and development of next generation histone deacetylase (HDAC) inhibitors, entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to support the clinical proof of concept study for MEKTOVI® (binimetinib) in combination with OKI-179, a highly potent and tolerable Class I HDAC inhibitor currently in Phase I for the treatment of NRAS melanoma.

• Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

  9/15/2020

  Sept. 15, 2020 17:45 UTC Company has 89 pipeline projects spread across 6 targeted therapeutic areas with 4 programs in registration and 23 in Phase 3 27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame Pipeline contributes to the Company’s expectation of at least 6% revenue CAGR over the next five years – and delivery of longer-term topline growth beyond that period Maj

• Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn

  9/15/2020

  The Companies Have Also Received Approvals in Australia and New Zealand; Combination on Track to Close in Fourth Quarter 2020

• Pfizer Hosts Virtual Investor Day

  9/14/2020

  Pfizer Inc. (NYSE: PFE) will host its virtual Investor Day today and tomorrow: Monday, September 14, 2020 from 1:00 p.m. EDT to 3:45 p.m. EDT and Tuesday, September 15, 2020 from 10:00 a.m. EDT to 1:30 p.m. EDT. Pfizer business executives and scientific leadership will provide updates on the company’s progress in advancing its R&D pipeline, specifically on product candidates with blockbuster potential that are expected to

• Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020

  9/10/2020

  Pfizer Inc. (NYSE:PFE) announced today that more than 50 abstracts representing data from nine approved and investigational Pfizer medicines, including several biomarker-driven and immuno-therapies, will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 being held from September

• Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020

  9/3/2020

  Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its virtual Investor Day held over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to 4:00 p.m. EDT and Tuesday, September 15, 2020 from 10:00 a.m. EDT to 1:00 p.m. EDT. Pfizer business executives and scientific leadership will provide updates on the company’s progress in advancing its R&D pipeline, specifically on pro

• ICON Signs New Service Agreement With Pfizer

  4/3/2020

  ICON plc, (NASDAQ: ICLR) a leading global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc. (NYSE:PFE)